Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.37M Buy
64,920
+10,187
+19% +$679K 0.03% 485
2026
Q1
$3.44M Buy
54,733
+27,150
+98% +$1.89M 0.03% 508
2025
Q4
$1.83M Sell
27,583
-20,255
-42% -$1.31M 0.01% 613
2025
Q3
$3.22M Buy
47,838
+44,789
+1,469% +$3.54M 0.03% 405
2025
Q2
$266K Sell
3,049
-34
-1% -$2.67K ﹤0.01% 1019
2025
Q1
$211K Sell
3,083
-237
-7% -$19.3K ﹤0.01% 1038
2024
Q4
$258K Buy
+3,320
New +$246K ﹤0.01% 866

Other funds holding DXCM

Waverly Advisors's DXCM Position: Q2 2026 in Review

Waverly Advisors increased its DexCom (DXCM) stake by 19% in Q2 2026, buying an estimated $679K and bringing the position to 64,920 shares worth $4.37M. The position accounts for 0.03% of the portfolio, ranked #485.

Waverly Advisors first reported a position in DXCM in Q4 2024 and has held it in 7 quarters since. 976 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Waverly Advisors held 64,920 shares of DexCom worth $4.37M as of Q2 2026.
  • Waverly Advisors bought 10,187 DexCom shares in Q2 2026, an estimated $679K.
  • DexCom made up 0.03% of Waverly Advisors's portfolio in Q2 2026, its #485 holding.
  • Waverly Advisors first reported a position in DexCom in Q4 2024 and has held it in 7 quarters since.
  • 976 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.